

# Pilar Vizcarra

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1702777/pilar-vizcarra-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30  
papers

338  
citations

7  
h-index

18  
g-index

37  
ext. papers

532  
ext. citations

4.7  
avg, IF

3.54  
L-index

#	Paper	IF	Citations
30	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. <i>Lancet HIV</i> , 2020, 7, e554-e564	7.8	172
29	Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. <i>HIV Medicine</i> , 2021, 22, 372-378	2.7	52
28	COVID-19 in HIV-Infected Individuals: Preliminary Results of a Prospective Cohort. <i>SSRN Electronic Journal</i> ,	1	11
27	Weight gain in people living with HIV switched to dual therapy: changes in body fat mass. <i>Aids</i> , 2020, 34, 155-157	3.5	11
26	Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients. <i>Antiviral Therapy</i> , 2019, 24, 467-471	1.6	10
25	Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. <i>HIV Research and Clinical Practice</i> , 2019, 20, 64-72	1.7	9
24	Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers. <i>Emerging Microbes and Infections</i> , 2021, 10, 493-496	18.9	8
23	T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity. <i>Clinical and Translational Immunology</i> , 2021, 10, e1341	6.8	7
22	Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. <i>HIV Medicine</i> , 2019, 20, 648-656	2.7	6
21	SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 916.e1-916.e4	9.5	6
20	Progressive and Parallel Decline of Humoral and T-Cell Immunity in Convalescent Healthcare Workers with Asymptomatic or Mild-to-Moderate Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 241-245	7	5
19	Carbapenemase-producing infections in COVID-19 patients. <i>Infectious Diseases</i> , 2021, 1-10	3.1	5
18	CD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment. <i>International Journal of STD and AIDS</i> , 2019, 30, 656-662	1.4	4
17	Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. <i>International Journal of STD and AIDS</i> , 2020, 31, 467-473	1.4	4
16	Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy. <i>Infectious Diseases</i> , 2020, 52, 202-206 <sup>3.1</sup>		4
15	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19	7	4
14	COVID-19 and geographical area of origin. <i>Clinical Microbiology and Infection</i> , 2021, 27, 632.e1-632.e5	9.5	4

13	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1955-1960	5.1	2
12	Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice. <i>CJC Open</i> , <b>2019</b> , 1, 245-255 <sup>2</sup>		2
11	IFN- $\gamma$ cell response and IFN- $\gamma$ release concordance after in vitro SARS-CoV-2 stimulation. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13636	4.6	2
10	Symtuza in clinical practice. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2018</b> , 36 Suppl 2, 31-36	0.9	2
9	Expansion of CD56CD16 NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients.. <i>Viruses</i> , <b>2021</b> , 14,	6.2	2
8	Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity.. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 812729	5.7	1
7	Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1046-1050	5.1	1
6	Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.. <i>Vaccine: X</i> , <b>2022</b> , 11, 100165	3.8	1
5	Implementation of a lung cancer screening initiative in HIV-infected subjects. <i>PLoS ONE</i> , <b>2021</b> , 16, e0260069	3.69	0
4	Evaluation of the fracture risk assessment tool for determining bone disease and the impact of secondary causes of osteoporosis in people living with HIV. <i>HIV Research and Clinical Practice</i> , <b>2020</b> , 21, 63-71	1.7	
3	Progression Risk in People with HIV and COVID-19: Predictive Performance of Current Risk Scores. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 613-619	1.6	
2	[Prevalence of low bone mass in individuals with HIV infection]. <i>Medicina Clínica</i> , <b>2021</b> , 157, 234-237	1	
1	Prevalence of low bone mass in individuals with HIV infection. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 157, 234-237	0.3	